New study tracks xeljanz safety in kids with arthritis
NCT ID NCT05754710
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study looks at the safety and effectiveness of the drug Xeljanz in children aged 2 to 17 with active juvenile idiopathic arthritis or juvenile psoriatic arthritis. It is an observational study in Korean clinics, meaning doctors prescribe the drug as usual and researchers monitor results for up to 44 weeks. The goal is to track any side effects and see how well the drug works in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for kids with arthritis: Long-Term drug study launches
- Ultrasound reveals hidden tendon problems in kids with arthritis
- Engineered immune cells aim to tame childhood arthritis and lupus
- New combo therapy shows promise for kids with stubborn arthritis
- New study tests if adding a biologic drug helps kids with arthritis
- New IV drug shows promise for kids with stubborn arthritis